ASH 2016 | Developments in CML over the past 30 years and where we are today
Rüdiger Hehlmann, MD of Heidelberg University, Heidelberg, Germany discusses developments in chronic myeloid leukemia (CML) over the past 30 years. Prof. Hehlmann explains that the introduction of interferon and tyrosine kinase inhibitors (TKIs) were key developments in CML. Further, he mentions that he is involved in randomized clinical trials of imatinib in combinations or at various doses. He concludes by highlighting that 30 years ago, every CML patient died of the disease but today, the life expectancy compared to the general population is 92%, i.e. most patients have a normal life expectancy.
Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up